Pituitary Gland Carcinoma

The endoscopic transsphenoidal approach has proven to be a safe and highly effective method for achieving GTR in patients with PPTs. Spindle cell oncocytoma, with a higher level of vascularization than PC and GCT, poses a greater risk of surgical complicationsand may result in non-GTR.

This case illustrates the rare presentation of a PIT-1 lineage adenoma secreting biologically active TSH, GH, and prolactin. Comprehensive hormonal evaluation and long-term biochemical and radiologic surveillance are essential, given the risk of incomplete remission despite apparent surgical cure.

This report describes a non-diabetic cat with HST secondary to a pituitary macroadenoma achieving sustained clinical and biochemical control with cabergoline monotherapy. This case demonstrates that a dopamine agonist might be an effective medical option in selected non-diabetic cats with HST, even in the presence of a large pituitary mass and signs of neurologic disease.

Although mice with Rb1 gene inactivation invariably develop pituitary adenomas, and some evidence suggests that a subset of pituitary adenomas have lack or reduced expression of Rb protein, to date no evidence has been reported that patients with germline mutations in the RB1 gene (that encodes for Rb protein) are at risk of developing pituitary adenomas. Here, we report the case of a patient with childhood (age 1 year) onset retinoblastoma because of a germline pathogenic variant of the RB1 gene who presented with a somatotropinoma diagnosed at a young age (20) and whose pituitary adenoma cells showed loss of expression of Rb protein by immunohistochemistry, suggesting a role of Rb in preventing the development of pituitary adenomas.

P2, N=10, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed

P=N/A, N=102, Not yet recruiting, Uludag University

On multivariate Cox regression, Type 2 (hazard ratio [HR] = 2.76, 95% CI: 1.86-7.81, P = .009), and Type 3 (HR = 4.69, 95% CI: 1.65-13.3, P = .004) exhibited significantly higher mortality risk vs Type 1, independent of treatment modalities and presence of comorbidities. Applying a structural-functional acromegaly classification enables distinction of significant differences in long-term survival outcomes.

P1, N=50, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting

This report highlights the critical need for comprehensive clinical evaluations in patients with common metabolic disorders, such as diabetes mellitus, to identify rare underlying causes and ensure timely diagnosis. Furthermore, it examines potential mechanisms of ketosis in acromegaly and reviews current approaches to glycemic management in this population, where evidence-based guidelines remain limited.

This case underscores the necessity of extended immunohistochemical profiling and molecular genetic sequencing of pituitary tumors to facilitate development of personalized therapeutic strategies for aggressive somatotropinomas refractory to standard treatment modalities.

This study identifies a PTTG1-DLX2-β-catenin signaling axis that drives LUAD malignant progression. These findings highlight PTTG1 as an important molecular driver and a potential therapeutic target in LUAD.

The prevalence of biochemical discordance in our cohort was 19.5%. The predominant pattern was elevated IGF-1 levels with a normal nadir GH. The discordant group had higher IGF-1 at diagnosis, suggesting that greater preoperative disease activity may predispose to postoperative biochemical discordance.